Latest Manufacturing News

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.

Metal Powder Works has scaled its NextGen powder production to 100 metric tonnes per annum with an industry-leading saleable yield above 95%, setting the stage for an 800MT capacity by 2028 at a fraction of conventional costs.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

RocketDNA Ltd delivered a break-even operating cash flow quarter with $2.47 million revenue, driven by soaring autonomous drone usage and the debut of its Skylink® operating system.

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Parkway Corporate Limited delivered a record $5.21 million quarterly revenue and $0.73 million EBITDA in Q3 FY26, driven by ramp-up of a major water infrastructure project. Meanwhile, its flagship Queensland Brine Management Complex progresses through key development application milestones with public notification underway.

Sovereign Metals' March 2026 update reveals a robust DFS for its Kasiya Rutile-Graphite Project, a substantial resource upgrade, strategic offtake MOUs, and a high-value heavy rare earth by-product discovery.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

PT ANTAM TBK sustained strong operational performance in Q1 2026 with robust gold and nickel sales amid favourable market trends, while pushing forward strategic mineral downstreaming projects including Indonesia's integrated battery ecosystem.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.